That’s why, as a 2016 Vox investigation found, there are many reports of vitamins and supplements containing ingredients that ...

Hims and Hers' stock fell over 19% in after-hours trading on Monday after its CEO said the company would no longer sell compounded versions of mega-hit weight loss drugs. "We will have to start ...

Hims & Hers shares fell on Tuesday, a day after the company released fourth-quarter results that disappointed on gross margin and outlined changes to its weight loss business. The company reported ...

Hims & Hers (HIMS) stock is sinking 20% today after Eli Lilly (LLY) unveiled significantly cheaper versions of its popular weight-loss drugs today. Additionally, the FDA last week hindered the ...

Hims & Hers reported a double beat with Q4 revenue at $481M, a 95% YoY improvement, but faced an 18% stock drop after hours. Despite margin contraction due to new weight loss offerings, adjusted ...

Hims & Hers Health (HIMS) has seen its shares decline over 17% in the past week since the U.S. Food and Drug Administration (FDA) announced the resolution of the shortage of GLP-1 (semaglutide ...

Hims stock, Texas Tech basketball, Oscars, Detroit Pistons 25-02-2025 , 08:39:35 ARGENTINA Starlink, Barracas Central Newell's, Argentinos Juniors, Tigre Banfield, Nueva Chicago Chacarita, Clima ...

Bloomberg / Contributor / Getty Images Shares of Hims & Hers Health (HIMS) plunged in late trading Monday after the company reported falling margins as costs rose, overshadowing better-than ...

Hims & Hers Health reported fourth-quarter results on Monday that beat analysts' expectations, but the stock sank in extended trading. Revenue increased 95% from a year earlier to $481 million ...

Direct-to-consumer telehealth company Hims & Hers is forging ahead in the aftermath of the semaglutide shortage ending last week. Hims & Hers faces new headwinds in its weight management segment ...